Highlights
- Chimeric has received patent allowance in Japan for chlorotoxin.
- The latest development has expanded the scope of patent protection as it covers a wider range of CLTX CAR construct designs.
- Japan is the world’s third largest pharmaceutical market, highlights CHM.
Cell therapy-focused company Chimeric Therapeutics Limited (ASX: CHM) has received a patent allowance in Japan for application JP2022007016A, which includes specific applications of chimeric antigen receptor (CAR) technology employing chlorotoxin (CLTX). It includes the company’s CAR NK asset CHM 1301 under preclinical-stage trials and CAR T asset CHM 1101 (clinical-stage).
The company received initial patent protection in Japan for CLTX CAR technology in 2022, and the newly granted allowance increases the scope of protection as it covers a wider range of CLTX CAR construct designs.
Data source: company update
CHM referring to IQVIA highlighted that Japan is the third largest pharmaceutical market globally. In Japan, innovative speciality products have been registering double-digit compound growth and accessibility and use of biologics are expanding continuously.
The shares of CHM traded at AU$0.040 apiece at the time of writing on 27 July 2023.